Garetosmab
Based on 1 publication(s) in Google Scholar
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.57%
- CAS No.: 2097125-54-5
- Masse moléculaire:145.52 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99355
BimagrumabAnti-ACVR2B Antibody -
HY-P99388
TrevogrumabAnti-GDF8 Antibody -
HY-P99370
LandogrozumabAnti-Myostatin Antibody -
HY-P99020
FresolimumabTGF-β Inhibitor -
HY-P99590
SotaterceptACVR2A-IgG Fc Fusion Protein -
HY-P99857
DomagrozumabMyostatin Inhibitor -
HY-P99003
Human IgG4 (S228P) kappa, Isotype ControlIgG4κ Isotype Control -
HY-P9907
TrastuzumabHER2 Blocking Antibody -
HY-P99441
ApitegromabMonoclonal Antibody -
HY-P99518
Taldefgrobep alfaMyostatin Inhibitor
Publications Citing Use of MedChemExpress (MCE) Garetosmab
More
Activité biologique
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
INHBA/Activin A
In Vitro
Garetosmab (REGN 2477) specifically binds to and blocks signaling of activin proteins containing the inhibin βα subunit (activins A, AB, and AC). In vitro, Garetosmab has high affinity and specificity for activins A, AB, and AC, but does not bind or functionally inhibit other TGF-β family ligands that share the same activin receptor pathways, including activin B, inhibin A, BMP-2, BMP6, BMP9, BMP10, GDF8, and GDF11[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human Latent Activin A/INHBA Protein, His Tag can bind Garetosmab. The EC50 for this effect is 15.03 ng/mL.
Chemical Information
-
CAS No. 2097125-54-5
-
Appearance Liquid
-
Masse moléculaire 145.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Garetosmab]
-
Synonyms
REGN 2477
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control. [Abstract]2025 Jun 6;15(1):19887. PMID: 40481031
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Garetosmab Related Classifications
HY-P99632 Related Classifications
Powered by Bioz